A safety and feasibility trial of 131I‐MIBG in newly diagnosed high‐risk neuroblastoma: A Children’s Oncology Group study
Weiss, Brian D.; Yanik, Gregory; Naranjo, Arlene; Zhang, Fan F.; Fitzgerald, Wendy; Shulkin, Barry L.; Parisi, Marguerite T.; Russell, Heidi; Grupp, Stephan; Pater, Luke; Mattei, Peter; Mosse, Yael; Lai, Hollie A.; Jarzembowski, Jason A.; Shimada, Hiroyuki; Villablanca, Judith G.; Giller, Roger; Bagatell, Rochelle; Park, Julie R.; Matthay, Katherine K.
2021-10
View/ Open
Citation
Weiss, Brian D.; Yanik, Gregory; Naranjo, Arlene; Zhang, Fan F.; Fitzgerald, Wendy; Shulkin, Barry L.; Parisi, Marguerite T.; Russell, Heidi; Grupp, Stephan; Pater, Luke; Mattei, Peter; Mosse, Yael; Lai, Hollie A.; Jarzembowski, Jason A.; Shimada, Hiroyuki; Villablanca, Judith G.; Giller, Roger; Bagatell, Rochelle; Park, Julie R.; Matthay, Katherine K. (2021). "A safety and feasibility trial of 131I‐MIBG in newly diagnosed high‐risk neuroblastoma: A Children’s Oncology Group study." Pediatric Blood & Cancer 68(10): n/a-n/a.
Abstract
Introduction131I‐meta‐iodobenzylguanidine (131I‐MIBG) is effective in relapsed neuroblastoma. The Children’s Oncology Group (COG) conducted a pilot study (NCT01175356) to assess tolerability and feasibility of induction chemotherapy followed by 131I−MIBG therapy and myeloablative busulfan/melphalan (Bu/Mel) in patients with newly diagnosed high‐risk neuroblastoma.MethodsPatients with MIBG‐avid high‐risk neuroblastoma were eligible. After the first two patients to receive protocol therapy developed severe sinusoidal obstruction syndrome (SOS), the trial was re‐designed to include an 131I‐MIBG dose escalation (12, 15, and 18 mCi/kg), with a required 10‐week gap before Bu/Mel administration. Patients who completed induction chemotherapy were evaluable for assessment of 131I‐MIBG feasibility; those who completed 131I‐MIBG therapy were evaluable for assessment of 131I‐MIBG + Bu/Mel feasibility.ResultsFifty‐nine of 68 patients (86.8%) who completed induction chemotherapy received 131I‐MIBG. Thirty‐seven of 45 patients (82.2%) evaluable for 131I‐MIBG + Bu/Mel received this combination. Among those who received 131I‐MIBG after revision of the study design, one patient per dose level developed severe SOS. Rates of moderate to severe SOS at 12, 15, and 18 mCi/kg were 33.3%, 23.5%, and 25.0%, respectively. There was one toxic death. The 131I‐MIBG and 131I‐MIBG+Bu/Mel feasibility rates at the 15 mCi/kg dose level designated for further study were 96.7% (95% CI: 83.3%‐99.4%) and 81.0% (95% CI: 60.0%‐92.3%).ConclusionThis pilot trial demonstrated feasibility and tolerability of administering 131I‐MIBG followed by myeloablative therapy with Bu/Mel to newly diagnosed children with high‐risk neuroblastoma in a cooperative group setting, laying the groundwork for a cooperative randomized trial (NCT03126916) testing the addition of 131I‐MIBG during induction therapy.Publisher
Wiley Periodicals, Inc.
ISSN
1545-5009 1545-5017
Other DOIs
Types
Article
Metadata
Show full item recordCollections
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.